10 Potential Drug Approvals To Look Out For In 2016
This article was originally published in Scrip
2015 was a busy year for both the US FDA and the EMA, with both agencies reporting a substantial uptick in the numbers of novel products they approved, but what product approval decisions are due in 2016?
You may also be interested in...
Regeneron Pharmaceuticals Inc. executives emphasized the blockbuster potential of product candidates in the company's late-stage research and development pipeline on Aug. 4, while noting that the top-selling biologic Eylea (aflibercept) is facing increased reimbursement and competitive pressures.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.